Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. (Q54282566)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Ya-Zhen Qin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lan-Ping Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Huan Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Qian Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yu Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hao Jiang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xiao-Hui Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Wei Han

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yu-Hong Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Feng-Rong Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jing-Zhi Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hong-Hu Zhu

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yan-Rong Liu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Bin Jiang

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kai-Yan Liu

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

12 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

56

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3116-3123

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Bl

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1032964

21 January 2018

Identifiers

10.3109/10428194.2015.1032964

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25804769%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54282566&oldid=1534952897"